02/22/2024

GSK's Injectable HIV Drug Shows Promise over Daily Pills

Cabenuva has shown superior efficacy in maintaining viral load suppression

On Wednesday, British drugmaker GSK said its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing challenges with pill intake.

The interim analysis of a late-stage trial on the therapy known as Cabenuva demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of adherence challenges to oral antiretroviral treatment, which is used to suppress and mitigate the progression of the disease.

The lack of consistent adherence is a common reason why some people living with HIV struggle to keep the virus in check, GSK said.

Please select this link to read the complete article from Reuters.